A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis

Neoplasia (United States)

Volumn 14, Issue 6, 2012, Pages 547-558

  Qiu, Xiaoxue ^a   Guo, Guijie ^a   Chen, Ke ^a   Kashiwada, Masaki ^b,d   Druker, Brian J ^c   Rothman, Paul B ^b   Chen, Ji Long ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF IOWA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; ELONGIN BC; GLIAL FIBRILLARY ACIDIC PROTEIN; JANUS KINASE 1; JANUS KINASE 2; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; STAT PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN BINDING; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84865647234     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1596/neo.12230     Document Type: Article

References (47)

1. Murray PJ (2007). The JAK-STAT signaling pathway: input and output integration. J Immunol 178, 2623-2629.
2. Danial NN and Rothman P (2000). JAK-STAT signaling activated by Abl oncogenes. Oncogene 19, 2523-2531.
3. Van Etten RA (2007). Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med 204, 461-465.
4. Helgason GV, Karvela M, and Holyoake TL (2011). Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 118, 2035-2043.
5. Chai SK, Nichols GL, and Rothman P (1997). Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159, 4720-4728.
6. Shuai K, Halpern J, ten Hoeve J, Rao X, and Sawyers CL (1996). Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13, 247-254.
7. Ilaria RL Jr and Van Etten RA (1996). P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271, 31704-31710.
8. Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, and Arlinghaus RB (2001). Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20, 6188-6195.
9. Samanta AK, Lin H, Sun T, Kantarjian H, and Arlinghaus RB (2006). Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 66, 6468-6472.
10. Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, Priebe W, and Arlinghaus R (2011). Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25, 463-472.
11. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, et al. (2011). High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 117, 3409-3420.
12. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, et al. (2011). The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117, 3421-3429.
13. Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, et al. (2010). Stat5 is indispensable for the maintenance of Bcr/Abl-positive leukaemia. EMBO Mol Med 2, 98-110.
14. [] Wormald S and Hilton D (2003). Inhibitors of cytokine signal transduction. J Biol Chem 279, 821-824.
15. Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, et al. (1999). The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 96, 2071-2076.
16. Ungureanu D, Saharinen P, Junttila I, Hilton DJ, and Silvennoinen O (2002). Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 22, 3316-3326.
17. Waiboci LW, Ahmed CM, Mujtaba MG, Flowers LO, Martin JP, Haider MI, and Johnson HM (2007). Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J Immunol 178, 5058-5068.
18. Galm O, Yoshikawa H, Esteller M, Osieka R, and Herman JG (2003). SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101, 2784-2788.
19. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, and Herman JG (2001). SOCS-1, a negative regulator of the JAK/ STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28, 29-35.
20. Saudemont A, Hamrouni A, Marchetti P, Liu J, Jouy N, Hetuin D, Colucci F, and Quesnel B (2007). Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. Cancer Res 67, 4491-4498.
21. Melzner I, Bucur AJ, Bruderlein S, Dorsch K, Hasel C, Barth TF, Leithauser F, and Moller P (2005). Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105, 2535-2542.
22. Weniger MA, Melzner I, Menz CK, Wegener S, Bucur AJ, Dorsch K, Mattfeldt T, Barth TFE, and Möller P (2006). Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25, 2679-2684.
23. Mottok A, Renne C, Willenbrock K, Hansmann ML, and Brauninger A (2007). Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 110, 3387-3390.
24. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, and Jablons DM (2003). SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100, 14133-14138.
25. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T, and Yoshikawa H (2005). Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24, 6406-6417.
26. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C, and Tannapfel A (2005). SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24, 6699-6708.
27. Barclay JL, Anderson ST, Waters MJ, and Curlewis JD (2009). SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int J Cancer 124, 1756-1766.
28. Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C, Wasik M, and Odum N (2005). Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNβ. Leukemia 19, 209-213.
29. Liu TC, Lin SF, Chang JG, Yang MY, Hung SY, and Chang CS (2003). Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol 123, 654-661.
30. Hatirnaz O, Ure U, Ar C, Akyerli C, Soysal T, Ferhanoǧlu B, Özçelik T, and Ozbek U (2007). The SOCS-1 gene methylation in chronic myeloid leukemia patients. Am J Hematol 82, 729-730.
31. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Cervantes F, Barrios M, Colomer D, Heiniger A, and Torres A (2004). The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-β. Haematologica 89, 42-48.
32. Cacalano NA, Sanden D, and Johnston JA (2001). Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat Cell Biol 3, 460-465.
33. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W, Percy MJ, McMullin MF, Constantinescu SN, and Johnston JA (2007). The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 109, 4924-4929.
34. Elliott J, Suessmuth Y, Scott LM, Nahlik K, McMullin MF, Constantinescu SN, Green AR, and Johnston JA (2009). SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica 94, 576-580.
35. Chen XP, Losman JA, Cowan S, Donahue E, Fay S, Vuong BQ, Nawijn MC, Capece D, Cohan VL, and Rothman P (2002). Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci USA 99, 2175-2180.
36. [] Guo G, Qiu X, Wang S, Chen Y, Rothman PB, Wang Z, Wang G, and Chen JL (2010). Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. Oncogene 29, 3845-3853.
37. Chen JL, Limnander A, and Rothman PB (2008). Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 111, 1677-1685.
38. Limnander A, Danial NN, and Rothman PB (2004). v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells. Mol Cell 15, 329-341.
39. MacPartlin M, Smith AM, Druker BJ, Honigberg LA, and Deininger MW (2008). Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22, 1354-1360.
40. Ko J, Patel N, Ikawa T, Kawamoto H, Frank O, Rivera RR, Van Etten RA, and Murre C (2008). Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease. Proc Natl Acad Sci USA 105, 12967-12972.
41. Kamizono S, Hanada T, and Yasukawa H (2001). The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem 276, 12530-12538.
42. Gesbert F and Griffin JD (2000). Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 96, 2269-2276.
43. Yoshimura A, Nishinakamura H, Matsumura Y, and Hanada T (2005). Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther 7, 100-110.
44. Yoshimura A, Naka T, and Kubo M (2007). SOCS proteins, cytokine signaling and immune regulation. Nat Rev Immunol 7, 454-465.
45. Boyle K, Zhang JG, Nicholson SE, Trounson E, Babon JJ, McManus EJ, Nicola NA, and Robb L (2009). Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation. Cell Signal 21, 394-404.
46. Ghaith F, Abdou S, El-Bendary A, Shahin D, Eid M, Megeed WA, El-Sheikh I, Farrag W, and Yousuf S (2010). Prognostic relevance of 9q34 deletion and the suppressor of cytokine signalling-1 in CML patients. Int J Lab Hematol 32, 103-112.
47. Sakai I, Takeuchi K, Yamauchi H, Narumi H, and Fujita S (2002). Constitutive expression of SOCS3 confers resistance to IFN-β in chronic myelogenous leukemia cells. Blood 100, 2926-2931.